• Title of article

    Urocortin 2 Infusion in Healthy Humans: Hemodynamic, Neurohormonal, and Renal Responses Original Research Article

  • Author/Authors

    Mark E. Davis، نويسنده , , Christopher J. Pemberton، نويسنده , , Timothy G. Yandle، نويسنده , , Steve F. Fisher، نويسنده , , John G. Lainchbury، نويسنده , , Christopher M. Frampton، نويسنده , , Miriam T.Rademaker، نويسنده , , A. Mark Richards، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 2007
  • Pages
    11
  • From page
    461
  • To page
    471
  • Abstract
    Objectives We sought to examine the effects of urocortin (UCN) 2 infusion on hemodynamic status, cardiovascular hormones, and renal function in healthy humans. Background Urocortin 2 is a vasoactive and cardioprotective peptide belonging to the corticotrophin-releasing factor peptide family. Recent reports indicate the urocortins exert important effects beyond the hypothalamo-pituitary-adrenal axis upon cardiovascular and vasohumoral function in health and cardiac disease. Methods We studied 8 healthy unmedicated men on 3 separate occasions 2 to 5 weeks apart. Subjects received placebo, 25-μg low-dose (LD), and 100-μg high-dose (HD) of UCN 2 intravenously over the course of 1 h in a single-blind, placebo-controlled, dose-escalation design. Noninvasive hemodynamic indexes, neurohormones, and renal function were measured. Results The administration of UCN 2 dose-dependently increased cardiac output (mean peak increments ± SEM) (placebo 0.5 ± 0.2 l/min; LD 2.1 ± 0.6 l/min; HD 5.0 ± 0.8 l/min; p < 0.001), heart rate (placebo 3.3 ± 1.0 beats/min; LD 8.8 ± 1.8 beats/min; HD 17.8 ± 2.1 beats/min; p < 0.001), and left ventricular ejection fraction (placebo 0.6 ± 1.4%; LD 6.6 ± 1.5%; HD 14.1 ± 0.8%; p < 0.001) while decreasing systemic vascular resistance (placebo −128 ± 50 dynes·s/cm5; LD −407 ± 49 dynes·s/cm5; HD −774 ± 133 dynes·s/cm5; p < 0.001). Activation of plasma renin activity (p = 0.002), angiotensin II (p = 0.001), and norepinephrine (p < 0.001) occurred only with the higher 100-μg dose. Subtle decreases in urine volume (p = 0.012) and natriuresis (p = 0.001) were observed. Conclusions Brief intravenous infusions of UCN 2 in healthy humans induced pronounced dose-related increases in cardiac output, heart rate, and left ventricular ejection fraction while decreasing systemic vascular resistance. Subtle renal effects and activation of plasma renin, angiotensin II, and norepinephrine (at high-dose only) were observed. These findings warrant further investigation of the role of UCN 2 in circulatory regulation and its potential therapeutic application in heart disease.
  • Keywords
    A , ACTH , EM , E , CRF , Urocortin , AM , early diastolic myocardial velocity , SVR , systemic vascular resistance , corticotrophin-releasing factor , transmitral diastolic flow velocity with atrial contraction , adrenocorticotropic hormone , diastolic myocardial velocity during atrial contraction , transmitral early diastolic flow velocity , UCN
  • Journal title
    JACC (Journal of the American College of Cardiology)
  • Serial Year
    2007
  • Journal title
    JACC (Journal of the American College of Cardiology)
  • Record number

    472310